Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Jul;79(933):367–376. doi: 10.1136/pmj.79.933.367

Recombinant erythropoietin in clinical practice

T Ng 1, G Marx 1, T Littlewood 1, I Macdougall 1
PMCID: PMC1742767  PMID: 12897214

Abstract

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.

Full Text

The Full Text of this article is available as a PDF (216.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagnis C., Beaufils H., Jacquiaud C., Adabra Y., Jouanneau C., Le Nahour G., Jaudon M. C., Bourbouze R., Jacobs C., Deray G. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001 May;16(5):932–938. doi: 10.1093/ndt/16.5.932. [DOI] [PubMed] [Google Scholar]
  2. Bolaños Luis, Castro Pedro, Falcón Teresa G., Mouzo Ricardo, Varela José Manuel. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol. 2002 Jan-Feb;22(1):67–72. doi: 10.1159/000046676. [DOI] [PubMed] [Google Scholar]
  3. Busuttil D., Copplestone A. Management of blood loss in Jehovah's Witnesses. BMJ. 1995 Oct 28;311(7013):1115–1116. doi: 10.1136/bmj.311.7013.1115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Casadevall Nicole. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant. 2002;17 (Suppl 5):42–47. doi: 10.1093/ndt/17.suppl_5.42. [DOI] [PubMed] [Google Scholar]
  5. Casadevall Nicole, Nataf Joelle, Viron Beatrice, Kolta Amir, Kiladjian Jean-Jacques, Martin-Dupont Philippe, Michaud Patrick, Papo Thomas, Ugo Valerie, Teyssandier Irene. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002 Feb 14;346(7):469–475. doi: 10.1056/NEJMoa011931. [DOI] [PubMed] [Google Scholar]
  6. Cascinu S., Fedeli A., Del Ferro E., Luzi Fedeli S., Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol. 1994 May;12(5):1058–1062. doi: 10.1200/JCO.1994.12.5.1058. [DOI] [PubMed] [Google Scholar]
  7. Case D. C., Jr, Bukowski R. M., Carey R. W., Fishkin E. H., Henry D. H., Jacobson R. J., Jones S. E., Keller A. M., Kugler J. W., Nichols C. R. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993 May 19;85(10):801–806. doi: 10.1093/jnci/85.10.801. [DOI] [PubMed] [Google Scholar]
  8. Cazzola M., Messinger D., Battistel V., Bron D., Cimino R., Enller-Ziegler L., Essers U., Greil R., Grossi A., Jäger G. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995 Dec 15;86(12):4446–4453. [PubMed] [Google Scholar]
  9. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol. 2001 Jul;38(3 Suppl 7):33–39. doi: 10.1016/s0037-1963(01)90128-3. [DOI] [PubMed] [Google Scholar]
  10. Chikada M., Furuse A., Kotsuka Y., Yagyu K. Open-heart surgery in Jehovah's Witness patients. Cardiovasc Surg. 1996 Jun;4(3):311–314. doi: 10.1016/0967-2109(95)00135-2. [DOI] [PubMed] [Google Scholar]
  11. Christodoulou DK, Tsianos EV. Anemia in inflammatory bowel disease - the role of recombinant human erythropoietin. Eur J Intern Med. 2000 Aug;11(4):222–227. doi: 10.1016/s0953-6205(00)00094-7. [DOI] [PubMed] [Google Scholar]
  12. Corwin H. L., Gettinger A., Rodriguez R. M., Pearl R. G., Gubler K. D., Enny C., Colton T., Corwin M. J. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999 Nov;27(11):2346–2350. doi: 10.1097/00003246-199911000-00004. [DOI] [PubMed] [Google Scholar]
  13. Crawford Jeffrey, Cella David, Cleeland Charles S., Cremieux Pierre-Yves, Demetri George D., Sarokhan Brenda J., Slavin Mitchell B., Glaspy John A. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15;95(4):888–895. doi: 10.1002/cncr.10763. [DOI] [PubMed] [Google Scholar]
  14. Dammacco F., Silvestris F., Castoldi G. L., Grassi B., Bernasconi C., Nadali G., Perona G., De Laurenzi A., Torelli U., Ascari E. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res. 1998;28(2):127–134. doi: 10.1007/s005990050032. [DOI] [PubMed] [Google Scholar]
  15. Del Mastro L., Venturini M., Lionetto R., Garrone O., Melioli G., Pasquetti W., Sertoli M. R., Bertelli G., Canavese G., Costantini M. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997 Jul;15(7):2715–2721. doi: 10.1200/JCO.1997.15.7.2715. [DOI] [PubMed] [Google Scholar]
  16. Demetri G. D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998 Oct;16(10):3412–3425. doi: 10.1200/JCO.1998.16.10.3412. [DOI] [PubMed] [Google Scholar]
  17. Ehrenreich Hannelore, Hasselblatt Martin, Dembowski Christoph, Cepek Lukas, Lewczuk Piotr, Stiefel Michael, Rustenbeck Hans-Heino, Breiter Norbert, Jacob Sonja, Knerlich Friederike. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495–505. [PMC free article] [PubMed] [Google Scholar]
  18. Ekblom B. T. Blood boosting and sport. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):89–98. doi: 10.1053/beem.2000.0056. [DOI] [PubMed] [Google Scholar]
  19. Eknoyan G. The importance of early treatment of the anaemia of chronic kidney disease. Nephrol Dial Transplant. 2001;16 (Suppl 5):45–49. doi: 10.1093/ndt/16.suppl_5.45. [DOI] [PubMed] [Google Scholar]
  20. Eschbach J. W., Abdulhadi M. H., Browne J. K., Delano B. G., Downing M. R., Egrie J. C., Evans R. W., Friedman E. A., Graber S. E., Haley N. R. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989 Dec 15;111(12):992–1000. doi: 10.7326/0003-4819-111-12-992. [DOI] [PubMed] [Google Scholar]
  21. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  22. Eschbach J. W. Erythropoietin: the promise and the facts. Kidney Int Suppl. 1994 Jan;44:S70–S76. [PubMed] [Google Scholar]
  23. Fernandes C. J., Jr, Akamine N., De Marco F. V., De Souza J. A., Lagudis S., Knobel E. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. Crit Care. 2001 Nov 1;5(6):362–367. doi: 10.1186/cc1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Franz A. R., Pohlandt F. Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary? Arch Dis Child Fetal Neonatal Ed. 2001 Mar;84(2):F96–F100. doi: 10.1136/fn.84.2.F96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gershon Sharon K., Luksenburg Harvey, Coté Timothy R., Braun M. Miles. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002 May 16;346(20):1584–1586. doi: 10.1056/NEJM200205163462015. [DOI] [PubMed] [Google Scholar]
  26. Glaspy J., Jadeja J. S., Justice G., Kessler J., Richards D., Schwartzberg L., Rigas J., Kuter D., Harmon D., Prow D. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr;84 (Suppl 1):17–23. doi: 10.1054/bjoc.2001.1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Gorio Alfredo, Gokmen Necati, Erbayraktar Serhat, Yilmaz Osman, Madaschi Laura, Cichetti Cinzia, Di Giulio Anna Maria, Vardar Enver, Cerami Anthony, Brines Michael. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A. 2002 Jun 24;99(14):9450–9455. doi: 10.1073/pnas.142287899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Griffiths G., Lall R., Chatfield S., Short A., Mackay P., Williamson P., Brown J., Levene M. I. Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1997 May;76(3):F190–F192. doi: 10.1136/fn.76.3.f190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hamasaki N., Yamamoto M. Red blood cell function and blood storage. Vox Sang. 2000;79(4):191–197. doi: 10.1159/000056729. [DOI] [PubMed] [Google Scholar]
  30. Hast R., Wallvik J., Folin A., Bernell P., Stenke L. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res. 2001 Jan;25(1):13–18. doi: 10.1016/s0145-2126(00)00073-4. [DOI] [PubMed] [Google Scholar]
  31. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol. 1995 Jan;89(1):67–71. doi: 10.1111/j.1365-2141.1995.tb08909.x. [DOI] [PubMed] [Google Scholar]
  32. Hellström-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J., Ost A., Greenberg P. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997 Nov;99(2):344–351. doi: 10.1046/j.1365-2141.1997.4013211.x. [DOI] [PubMed] [Google Scholar]
  33. Henry D. H., Beall G. N., Benson C. A., Carey J., Cone L. A., Eron L. J., Fiala M., Fischl M. A., Gabin S. J., Gottlieb M. S. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med. 1992 Nov 1;117(9):739–748. doi: 10.7326/0003-4819-117-9-739. [DOI] [PubMed] [Google Scholar]
  34. Huraib S., Abu-Aisha H., al-Momen A., al-Wakeel J., Memon N., al-Tuwaijri A. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kidney Dis. 1997 Jun;29(6):866–870. doi: 10.1016/s0272-6386(97)90460-1. [DOI] [PubMed] [Google Scholar]
  35. Inoue N., Takeuchi M., Ohashi H., Suzuki T. The production of recombinant human erythropoietin. Biotechnol Annu Rev. 1995;1:297–313. doi: 10.1016/s1387-2656(08)70055-3. [DOI] [PubMed] [Google Scholar]
  36. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992 Apr;72(2):449–489. doi: 10.1152/physrev.1992.72.2.449. [DOI] [PubMed] [Google Scholar]
  37. Johnson C. A., Wakeen M., Taylor C. A., 3rd, Zimmerman S. W., Burkart J., Bhattacharya A., Kosorok M. R. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Perit Dial Int. 1999 Nov-Dec;19(6):578–582. [PubMed] [Google Scholar]
  38. Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen A. T., Man N. K. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001 Feb;16(2):307–312. doi: 10.1093/ndt/16.2.307. [DOI] [PubMed] [Google Scholar]
  39. Klaesson S. Clinical use of rHuEPO in bone marrow transplantation. Med Oncol. 1999 Apr;16(1):2–7. doi: 10.1007/BF02787351. [DOI] [PubMed] [Google Scholar]
  40. Law M. L., Cai G. Y., Lin F. K., Wei Q., Huang S. Z., Hartz J. H., Morse H., Lin C. H., Jones C., Kao F. T. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6920–6924. doi: 10.1073/pnas.83.18.6920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Ledbetter D. J., Juul S. E. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg. 2000 Feb;35(2):178–182. doi: 10.1016/s0022-3468(00)90006-x. [DOI] [PubMed] [Google Scholar]
  42. Linardaki G. D., Boki K. A., Fertakis A., Tzioufas A. G. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand J Rheumatol. 1999;28(3):189–191. doi: 10.1080/03009749950154293. [DOI] [PubMed] [Google Scholar]
  43. Linde T., Ekberg H., Forslund T., Furuland H., Holdaas H., Nyberg G., Tydén G., Wahlberg J., Danielson B. G. The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. Transplantation. 2001 Jan 15;71(1):79–82. doi: 10.1097/00007890-200101150-00013. [DOI] [PubMed] [Google Scholar]
  44. Littlewood T. J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 2001 Apr;28(2 Suppl 8):49–53. doi: 10.1016/s0093-7754(01)90213-1. [DOI] [PubMed] [Google Scholar]
  45. Macdougall I. C. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16 (Suppl 3):14–21. doi: 10.1093/ndt/16.suppl_3.14. [DOI] [PubMed] [Google Scholar]
  46. Macdougall I. C. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant. 1998;13 (Suppl 2):23–27. doi: 10.1093/ndt/13.suppl_2.23. [DOI] [PubMed] [Google Scholar]
  47. Meyer M. P. Anaemia of prematurity. Epidemiology, management and costs. Pharmacoeconomics. 1997 Oct;12(4):438–445. doi: 10.2165/00019053-199712040-00002. [DOI] [PubMed] [Google Scholar]
  48. Miller C. B., Jones R. J., Piantadosi S., Abeloff M. D., Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990 Jun 14;322(24):1689–1692. doi: 10.1056/NEJM199006143222401. [DOI] [PubMed] [Google Scholar]
  49. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A. 2001 Apr 17;98(9):5181–5186. doi: 10.1073/pnas.081275298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Moore R. D., Keruly J. C., Chaisson R. E. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):29–33. doi: 10.1097/00042560-199809010-00004. [DOI] [PubMed] [Google Scholar]
  51. Muirhead N., Bargman J., Burgess E., Jindal K. K., Levin A., Nolin L., Parfrey P. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis. 1995 Aug;26(2 Suppl 1):S1–24. doi: 10.1016/0272-6386(95)90645-2. [DOI] [PubMed] [Google Scholar]
  52. Möcks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron. 2000 Dec;86(4):455–462. doi: 10.1159/000045834. [DOI] [PubMed] [Google Scholar]
  53. Nelson C. L., Stewart J. G. Primary and revision total hip replacement in patients who are Jehovah's Witnesses. Clin Orthop Relat Res. 1999 Dec;(369):251–261. doi: 10.1097/00003086-199912000-00026. [DOI] [PubMed] [Google Scholar]
  54. Nemoto T., Yokota N., Keane W. F., Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001 Jan;59(1):246–251. doi: 10.1046/j.1523-1755.2001.00485.x. [DOI] [PubMed] [Google Scholar]
  55. Nowrousian M. R. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol. 1998 Aug;15 (Suppl 1):S19–S28. [PubMed] [Google Scholar]
  56. Obladen M., Maier R. F. Recombinant erythropoietin for prevention of anemia in preterm infants. J Perinat Med. 1995;23(1-2):119–126. doi: 10.1515/jpme.1995.23.1-2.119. [DOI] [PubMed] [Google Scholar]
  57. Osterborg A., Boogaerts M. A., Cimino R., Essers U., Holowiecki J., Juliusson G., Jäger G., Najman A., Peest D. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood. 1996 Apr 1;87(7):2675–2682. [PubMed] [Google Scholar]
  58. Peeters H. R., Jongen-Lavrencic M., Bakker C. H., Vreugdenhil G., Breedveld F. C., Swaak A. J. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int. 1999;18(5-6):201–206. doi: 10.1007/s002960050085. [DOI] [PubMed] [Google Scholar]
  59. Phair J. P., Abels R. I., McNeill M. V., Sullivan D. J. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results. Arch Intern Med. 1993 Dec 13;153(23):2669–2675. [PubMed] [Google Scholar]
  60. Pihlstedt P., Paulin T., Sundberg B., Nilsson B., Ringdén O. Blood transfusion in marrow graft recipients. Ann Hematol. 1992 Aug;65(2):66–70. doi: 10.1007/BF01698131. [DOI] [PubMed] [Google Scholar]
  61. Rachmilewitz E. A., Aker M. The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci. 1998 Jun 30;850:129–138. doi: 10.1111/j.1749-6632.1998.tb10470.x. [DOI] [PubMed] [Google Scholar]
  62. Regan F. A., Hewitt P., Barbara J. A., Contreras M. Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group. BMJ. 2000 Feb 12;320(7232):403–406. doi: 10.1136/bmj.320.7232.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Reiter P. D., Rosenberg A. A., Valuck R. J. Factors associated with successful epoetin alfa therapy in premature infants. Ann Pharmacother. 2000 Apr;34(4):433–439. doi: 10.1345/aph.19169. [DOI] [PubMed] [Google Scholar]
  64. Roback John D. CMV and blood transfusions. Rev Med Virol. 2002 Jul-Aug;12(4):211–219. doi: 10.1002/rmv.353. [DOI] [PubMed] [Google Scholar]
  65. Schefels J., Merz U., Hörnchen H. Die Prophylaxe der Frühgeborenenanämie mit rekombinantem humanen Erythropoietin: eine Kosten-Nutzen-Analyse. Z Geburtshilfe Neonatol. 1999 Dec;203 (Suppl 2):1–5. [PubMed] [Google Scholar]
  66. Shapira Y., Bairey O., Vatury M., Magen-Nativ H., Prokocimer M., Sagie A. Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: case reports and literature review. J Heart Valve Dis. 2001 Jul;10(4):431–435. [PubMed] [Google Scholar]
  67. Silberberg J. S., Rahal D. P., Patton D. R., Sniderman A. D. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol. 1989 Jul 15;64(3):222–224. doi: 10.1016/0002-9149(89)90462-1. [DOI] [PubMed] [Google Scholar]
  68. Silva M., Grillot D., Benito A., Richard C., Nuñez G., Fernández-Luna J. L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996 Sep 1;88(5):1576–1582. [PubMed] [Google Scholar]
  69. Silverberg D. S., Blum M., Agbaria Z., Deutsch V., Irony M., Schwartz D., Baruch R., Yachnin T., Steinbruch S., Iaina A. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001 Mar;55(3):212–219. [PubMed] [Google Scholar]
  70. Silverberg Donald S., Wexler Dov, Blum Miriam, Tchebiner Joseph Z., Sheps David, Keren Gad, Schwartz Doron, Baruch Ron, Yachnin Tatyana, Shaked Meital. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003 Jan;18(1):141–146. doi: 10.1093/ndt/18.1.141. [DOI] [PubMed] [Google Scholar]
  71. Silverberg Donald S., Wexler Dov, Iaina Adrian. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002 Dec;4(6):681–686. doi: 10.1016/s1388-9842(02)00115-0. [DOI] [PubMed] [Google Scholar]
  72. Smith R. E., Jr, Jaiyesimi I. A., Meza L. A., Tchekmedyian N. S., Chan D., Griffith H., Brosman S., Bukowski R., Murdoch M., Rarick M. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001 Apr;84 (Suppl 1):24–30. doi: 10.1054/bjoc.2001.1749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Soubasi V., Kremenopoulos G., Tsantali C., Savopoulou P., Mussafiris C., Dimitriou M. Use of erythropoietin and its effects on blood lactate and 2, 3-diphosphoglycerate in premature neonates. Biol Neonate. 2000 Nov;78(4):281–287. doi: 10.1159/000014280. [DOI] [PubMed] [Google Scholar]
  74. Spivak J. L. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994 Aug 15;84(4):997–1004. [PubMed] [Google Scholar]
  75. Stovall T. G. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery. J Reprod Med. 2001 May;46(5 Suppl):531–538. [PubMed] [Google Scholar]
  76. Strauss R. G. Erythropoietin and neonatal anemia. N Engl J Med. 1994 Apr 28;330(17):1227–1228. doi: 10.1056/NEJM199404283301709. [DOI] [PubMed] [Google Scholar]
  77. Tchernia G., Delhommeau F., Perrotta S., Cynober T., Bader-Meunier B., Nobili B., Rohrlich P., Salomon J. L., Sagot-Bevenot S., del Giudice E. M. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J. 2000;1(3):146–152. doi: 10.1038/sj.thj.6200022. [DOI] [PubMed] [Google Scholar]
  78. Tilbrook P. A., Klinken S. P. The erythropoietin receptor. Int J Biochem Cell Biol. 1999 Oct;31(10):1001–1005. doi: 10.1016/s1357-2725(99)00071-0. [DOI] [PubMed] [Google Scholar]
  79. Vamvakas E. C. Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin's lymphoma. Transfus Med Rev. 2000 Jul;14(3):258–268. doi: 10.1053/tm.20000.7395. [DOI] [PubMed] [Google Scholar]
  80. Volberding P. Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther. 2000 Sep;22(9):1004–1003. doi: 10.1016/s0149-2918(00)80081-8. [DOI] [PubMed] [Google Scholar]
  81. Wahlberg J., Jacobsson J., Odlind B., Tufveson G., Wikström B. Haemodilution in renal transplantation in patients on erythropoietin. Lancet. 1988 Dec 17;2(8625):1418–1418. doi: 10.1016/s0140-6736(88)90601-0. [DOI] [PubMed] [Google Scholar]
  82. Westenfelder Christof. Unexpected renal actions of erythropoietin. Exp Nephrol. 2002;10(5-6):294–298. doi: 10.1159/000065304. [DOI] [PubMed] [Google Scholar]
  83. Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986 Nov 22;2(8517):1175–1178. doi: 10.1016/s0140-6736(86)92192-6. [DOI] [PubMed] [Google Scholar]
  84. Wurnig C., Schatz K., Noske H., Hemon Y., Dahlberg G., Josefsson G., Milbrink J., Hamard C., Collaborative Study Group Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res. 2001 Sep-Dec;33(5-6):303–310. doi: 10.1159/000049723. [DOI] [PubMed] [Google Scholar]
  85. Yazicioğlu L., Eryilmaz S., Sirlak M., Inan M. B., Aral A., Taşz R., Eren N. T., Kaya B., Akalin H. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg. 2001 Oct;122(4):741–745. doi: 10.1067/mtc.2001.115426. [DOI] [PubMed] [Google Scholar]
  86. Zaoui P., Bayle F., Maurizi J., Foret M., DalSoglio S., Vialtel P. Early thrombosis in kidney grafted into patient treated with erythropoietin. Lancet. 1988 Oct 22;2(8617):956–956. doi: 10.1016/s0140-6736(88)92616-5. [DOI] [PubMed] [Google Scholar]
  87. ten Bokkel Huinink W. W., de Swart C. A., van Toorn D. W., Morack G., Breed W. P., Hillen H. F., van der Hoeven J. J., Reed N. S., Fairlamb D. J., Chan S. Y. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998 Sep;15(3):174–182. doi: 10.1007/BF02821936. [DOI] [PubMed] [Google Scholar]
  88. van Bommel J., de Korte D., Lind A., Siegemund M., Trouwborst A., Verhoeven A. J., Ince C., Henny C. P. The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion. 2001 Dec;41(12):1515–1523. doi: 10.1046/j.1537-2995.2001.41121515.x. [DOI] [PubMed] [Google Scholar]
  89. van Iperen C. E., Gaillard C. A., Kraaijenhagen R. J., Braam B. G., Marx J. J., van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000 Aug;28(8):2773–2778. doi: 10.1097/00003246-200008000-00015. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES